Develops technology to detect, characterize, and isolate rare cells like CTCs and CECs from whole blood for research and diagnostics.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
RareCyte is a life science research and diagnostic development company. The Company is focused on characterizing and isolating rare cells in the blood. RareCyte’s AccuCyte system is an open platform for the unbiased discovery and isolation of circulating tumor cells (CTCs) and circulating endothelial cells (CECs) from whole blood.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
RareCyte Management Team
RareCyte Valuations & Financials
View real-time NPM data on RareCyte stock including daily RareCyte stock price estimates, valuation history, and historical share price information. Access RareCyte financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track RareCyte pricing across six independent market signals. Looking for private company due diligence data sources on RareCyte? Get in touch to learn more.
Similar Companies
like RareCyte
Podium
Enterprise Software
Customer messaging platform enabling companies to connect at critical touch points.
Magic Potion Games
Media & Entertainment
Develops a virtual world where children can enjoy safe and magical social gaming experiences, prioritizing trust and fun.
NuCicer
Climate & Sustainability
Develops agricultural technology that breeds improved chickpea varieties to enhance nutrition, functionality, and sustainability in food production.
Outcomes4Me
Healthcare & Life Sciences
AI-driven platform empowering cancer patients to navigate treatment decisions with personalized guidance on clinical options and trial matching.
iCounter
Cybersecurity
Delivers proactive intelligence that detects bespoke cyber threats within an organization’s ecosystem and enables precision defense.
Divert
Climate & Sustainability
A company that provides technological solutions to automate food waste diversion, helping businesses turn waste into sustainable resources.
Freeform
Industrials
Produces industrial-grade metal components by harnessing AI-driven printing systems to streamline production.
Caliza
FinTech
Enables users to hold and transact in digital dollars via seamless, compliant infrastructure.
Yet Analytics
Enterprise Software
Turns behavior data into interactive insights to support smarter decisions.
FAQ
We have answers
RareCyte stock does not trade on public stock exchanges. RareCyte stock is considered a private security and you need to be an accredited investor to trade shares. To invest in RareCyte stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
RareCyte Stock does not trade on public stock exchanges. In order to sell RareCyte shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
RareCyte does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view RareCyte share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for RareCyte stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell RareCyte stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in RareCyte stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
RareCyte is a private company and has not had an IPO. There is currently no RareCyte IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to RareCyte IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
